- Home
- REVB vs VERO Comparison
REVB vs VERO Comparison
Compare REVB & VERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- VERO
- Stock Information
- Founded
- REVB 2020
- VERO N/A
- Country
- REVB United States
- VERO Canada
- Employees
- REVB N/A
- VERO N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- VERO Medical/Dental Instruments
- Sector
- REVB Health Care
- VERO Health Care
- Exchange
- REVB Nasdaq
- VERO Nasdaq
- Market Cap
- REVB 2.2M
- VERO 2.2M
- IPO Year
- REVB N/A
- VERO N/A
- Fundamental
- Price
- REVB $0.86
- VERO $3.18
- Analyst Decision
- REVB
- VERO
- Analyst Count
- REVB 0
- VERO 0
- Target Price
- REVB N/A
- VERO N/A
- AVG Volume (30 Days)
- REVB 2.8M
- VERO 3.1M
- Earning Date
- REVB 05-08-2025
- VERO 05-15-2025
- Dividend Yield
- REVB N/A
- VERO N/A
- EPS Growth
- REVB N/A
- VERO N/A
- EPS
- REVB N/A
- VERO N/A
- Revenue
- REVB N/A
- VERO $60,997,000.00
- Revenue This Year
- REVB N/A
- VERO N/A
- Revenue Next Year
- REVB N/A
- VERO $7.47
- P/E Ratio
- REVB N/A
- VERO N/A
- Revenue Growth
- REVB N/A
- VERO N/A
- 52 Week Low
- REVB $0.77
- VERO $2.10
- 52 Week High
- REVB $60.80
- VERO $17.49
- Technical
- Relative Strength Index (RSI)
- REVB 20.22
- VERO 65.91
- Support Level
- REVB $0.78
- VERO $2.31
- Resistance Level
- REVB $1.15
- VERO $2.49
- Average True Range (ATR)
- REVB 0.23
- VERO 0.24
- MACD
- REVB -0.15
- VERO 0.09
- Stochastic Oscillator
- REVB 3.38
- VERO 50.00
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.